Skip to main content

Table 3 FDG and FLT-PET imaging results

From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PET measure

FDG (N = 22)

FLT (N = 27)

Mean (range)

 

SUVmax (pre-therapy)

 All

3.0 (1.4–10.9)

3.0 (1.1–7.8)

 Ductal

3.1 (1.4–10.9)

3.5 (1.4–7.8)

 Lobular

3.0 (1.8–4.1)

1.6 (1.1–3.2)

SUVmax (post-therapy)

 All

2.5 (0.9–10.6)

2.0 (0.8–3.8)

 Ductal

2.5 (0.9–10.6)

2.2 (1.1–3.8)

 Lobular

2.3 (1.6–3.0)

1.3 (0.8–2.2)

SUVmax (percent change)

 All

 −17% (−45 to 28%)

 −26% (−77 to 7%)

 Ductal

 −17% (−45 to 28%)

 −30% (−77 to 7%)

 Lobular

 −19% (−27 to −11%)

 −15% (−33 to 1%)

SUVmax (unit change)

 All

 −0.5 (−1.3 to 0.7)

 −1.0 (−6.0 to 0.1)

 Ductal

 −0.5 (−1.3 to 0.7)

 −1.3 (−6.0 to 0.1)

 Lobular

 −0.7 (−1.1 to -0.2)

 −0.30 (−1.0 to 0.02)

  1. This table indicates the average uptake from both scans for FDG and FLT as well as the percent and unit change between pre- and post-therapy scans